[PTLA] Portola Pharmaceuticals, Inc.
Overview
Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
Market Capitalization:
Exchange: NASDAQ
The data is delayed by 15 minutes.
Strongest Trends Summary For PTLA
PTLA is in the long-term down -65% below S&P in 5 years.
Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max
Chart type: absolute | relative to S&P
Description: Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops product candidates in the fields of thrombosis and hematology. Its lead compound, Betrixaban, is an oral, once-daily Factor Xa inhibitor in Phase III study for hospital to home prophylaxis of venous thromboembolism (VTE) in acute medically ill patients. The company?s lead development candidate, Andexanet Alfa, is a recombinant protein designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or undergo emergency surgery. Andexanet Alfa focuses on entering into Phase III registration studies. It has clinical collaboration agreements with various manufacturers of direct Factor Xa inhibitors, including Bristol-Myers Squibb Company, Pfizer Inc., Bayer Pharma, AG, Janssen Pharmaceuticals, Inc., and Daiichi Sankyo, Inc. The company is also developing Cerdulatinib, which is in Phase I/II proof-of-concept study, an orally available kinase inhibitor that inhibits spleen t
Fundamental Ratios
| Shares Outstanding | EPS | EPS Growth - 4 Quarters | EPS Growth - Q/Q | ||||
| EPS Growth - Y/Y | Sales Growth - 4 Quarters | -2.28% | Sales Growth - Q/Q | -2.2% | P/E | ||
| P/E To EPS Growth | P/S | P/BV | Price/Cash Per Share | ||||
| Price/Free Cash Flow | ROA | -31.53% | ROE | -36.59% | ROI | ||
| Current Ratio | 9.89 | Quick Ratio | Long Term Debt/Equity | Debt Ratio | 0.1 | ||
| Gross Margin | Operating Margin | -1592.24% | Net Profit Margin | -1595.01% | Dividend Payout Ratio | ||
| Dividend Yield |
Fundamental Data
| Cash From Financing Activities | 113.04 M | Cash From Investing Activities | 9.44 M | Cash From Operating Activities | -47.15 M | Gross Profit | |
| Net Profit | -46.91 M | Operating Profit | -46.5 M | Total Assets | 486.3 M | Total Current Assets | 403.45 M |
| Total Current Liabilities | 40.79 M | Total Debt | Total Liabilities | 67.32 M | Total Revenue | 2.36 M |
Technical Data
| High 52 week | 37.76 | Low 52 week | 15.46 | Last close | 30.94 | Last change | 1.91% |
| RSI | 68.73 | Average true range | 1.39 | Beta | 1.71 | Volume | 8.33 M |
| Simple moving average 20 days | 15.82% | Simple moving average 50 days | 15.78% | Simple moving average 200 days | 14.08% |
Performance Data
| Performance Week | 24.76% | Performance Month | 18.27% | Performance Quart | -2.7% | Performance Half | 8.41% |
| Performance Year | -17.97% | Performance Year-to-date | 58.5% | Volatility daily | 3.23% | Volatility weekly | 7.23% |
| Volatility monthly | 14.81% | Volatility yearly | 51.32% | Relative Volume | 1513.75% | Average Volume | 1.04 M |
| New High | New Low |
News
2020-06-24 10:36:49 | Portola Pharmaceuticals Inc PTLA: Hedge Funds Are Cashing Out
2020-06-17 23:30:10 | Rigrodsky & Long, P.A. Files Class Action Suit Against Portola Pharmaceuticals, Inc.
2020-06-05 17:24:28 | SHAREHOLDER ALERT: WeissLaw LLP Reminds QUMU, TCO, PTLA, and WLTW Shareholders About Its Ongoing Investigations
2020-06-04 10:15:03 | KLXE, TORC, TERP, and PTLA SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers
2020-05-26 11:00:00 | MERGER ALERT - QES and PTLA: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
2020-05-22 13:00:00 | INVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm - MINI, WLTW, PTLA
2020-05-21 14:10:40 | SHAREHOLDER ALERT: WeissLaw LLP Reminds STML, PTLA, and QES Shareholders About Its Ongoing Investigations
2020-05-19 12:15:00 | IMPORTANT SHAREHOLDER ALERT: Halper Sadeh LLP Investigates Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm - TORC, KLXE, PTLA
2020-05-19 10:14:48 | KLXE, FSB, PTLA, and STML SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers
2020-05-18 16:02:00 | Portola Pharmaceuticals Announces Virtual 2020 Annual Stockholder Meeting
2020-05-18 14:00:00 | MERGER ALERT - STML and PTLA: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
2020-05-16 15:00:00 | INVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm - STML, KLXE, PTLA
2020-05-15 18:00:00 | SHAREHOLDER ALERT: Monteverde & Associates PC is Investigating the Following Transaction
2020-05-15 16:48:00 | Macy’s and Portola See Investor Activists Buy Up Stakes
2020-05-15 14:35:00 | MERGER ALERT - TERP, PTLA, and QES: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
2020-05-15 13:20:00 | INVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm
2020-05-14 17:30:20 | SHAREHOLDER ALERT: WeissLaw LLP Reminds STML, PTLA, QES, and TERP Shareholders About Its Ongoing Investigations
2020-05-14 08:00:00 | U.S. Centers for Medicare & Medicaid Services CMS Proposes Extending New Technology Add-on Payment NTAP Reimbursement for Portola Pharmaceuticals' Andexxa® for Third Year
2020-05-13 12:40:00 | INVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm - STML, KLXE, PTLA
2020-05-12 17:07:43 | Hedge Fund Tells Alexion Management to Sell Company
2020-05-12 09:51:13 | KLXE, PTLA, STML, and TORC SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers
2020-05-11 15:30:00 | SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies; Investors are Encouraged to Contact the Firm - STML, KLXE, PTLA
2020-05-11 13:40:58 | Lifshitz Law Firm, P.C. Announces Investigation of KLX Energy Services Holdings, Inc. KLXE, Portola Pharmaceuticals, Inc. PTLA, Stemline Therapeutics, Inc. STML and Zuora, Inc. ZUO
2020-05-11 10:05:02 | Portola Pharmaceuticals PTLA Reports Q1 Loss, Misses Revenue Estimates
2020-05-11 08:00:00 | Portola Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
2020-05-09 08:30:00 | SHAREHOLDER ALERT: Halper Sadeh LLP Investigates the Following Companies; Investors are Encouraged to Contact the Firm - TORC, WMGI, PTLA
2020-05-07 11:40:00 | Shareholder Alert: Halper Sadeh LLP Investigates the Following Companies; Investors are Encouraged to Contact the Firm - STML, KLXE, PTLA
2020-05-07 10:40:25 | KLXE, PTLA, and STML SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers
2020-05-06 13:39:00 | SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Portola Pharmaceuticals, Inc. - PTLA
2020-05-06 11:26:03 | Alexion ALXN Beats on Q1 Earnings & Sales, Lowers Guidance
2020-05-06 09:46:01 | Company News for May 6, 2020
2020-05-06 09:45:08 | Is Portola Pharmaceuticals NASDAQ:PTLA Using Debt Sensibly?
2020-05-05 23:35:00 | Shareholder Investigation: Halper Sadeh LLP Investigates the Following Companies; Investors are Encouraged to Contact the Firm - STML, KLXE, PTLA
2020-05-05 20:02:00 | SHAREHOLDER ALERT: WeissLaw LLP Investigates Portola Pharmaceuticals, Inc.
2020-05-05 16:02:00 | Portola Pharmaceuticals Cancels First Quarter 2020 Financial Results Webcast and Conference Call Following Agreement to be Acquired by Alexion
2020-05-05 15:10:00 | ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Portola Pharmaceuticals, Inc.
2020-05-05 14:23:00 | Moore Kuehn Encourages TORC, STML, KLXE, and PTLA Investors to Contact Law Firm
2020-05-05 13:00:00 | PORTOLA PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout
2020-05-05 12:42:00 | Why Portola Pharmaceuticals Is Skyrocketing Today
2020-05-05 12:39:00 | Portola Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether The Sale Of Portola Pharmaceuticals, Inc. Is Fair To Shareholders; Investors Are Encouraged To Contact The Firm
2020-05-05 12:30:00 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Portola Pharmaceuticals, Inc. to Alexion Pharmaceuticals, Inc. is Fair to Shareholders
2020-05-05 11:13:00 | Alexion Will Buy Portola Pharmaceuticals for $1.4B
2020-05-05 10:50:21 | Portola Pharmaceuticals: P/E Ratio Insights
2020-05-05 10:48:00 | Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Portola Pharmaceuticals, Inc. has obtained a Fair Price in its sale to Alexion Pharmaceuticals, Inc.
2020-05-05 10:42:00 | Alexion to Buy Portola for $18 a Share, or $1.41 Billion
2020-05-05 10:42:00 | Alexion Pharma to Buy Portola for $18-Share, or $1.41 Billion
2020-05-05 09:50:01 | Biotech Giant Alexion Swipes Blood Disease-Focused Portola In Buyout